Folic acid (folate) levels were measured in the serum of patients with various neurological diseases in Japan. Thirty-six patients showed decreased serum folate levels among 343 consecutive neurological patients (10.5%). Folate administration (15mg/d) to folate-deficient patients improved neurological symptoms in 24 of 36 cases (67%). Serum folate levels were significantly lower in female than in male folate-deficient patients. Folate deficient patients showed predominantly axonal neuropathy, which responded to folate sup plementation more markedly. Male patients more frequently exhibited neuropathy, espe cially demyelinating and motor-dominant neuropathy, than females. Anemia was corre lated with male sex and low serum folate levels. Male patients were more responsive than fe males to folate treatment. More male patients had taken excess alcohol or received gastrec tomies than females. Neurological symptoms were more frequently improved by folate sup plementation in patients with neuropathy than exclusive encephalopathy. Serum folate lev els were lower in patients with encephalopathy, especially those with dementia, while folate therapy was more effective in neurological patients without dementia. Dysgeusia and ane mia improved in all patients after folate administration. Neurological patients with malab sorption or treated with continuous drip infusion were resistant to folate therapy. Since fo late-responsive neuroencepahlopathies are not rare among patients with neurological dis eases in Japan, the serum folate level would serve as a valuable indicator for folate supple ment therapy.
Folic acid (folate) is required to transfer one carbon units in the de novo synthesis of nucleotides and amino acids including methionine. Experimental results with folate-deficient mice suggest a neurochemical change in the serotonin and dopamine system (1) . Neurological symptoms associated with folate-deficiency have been reported in an increasing number of patients, occasion ally suggesting a causal relationship between a decrease in serum folate level and central or peripheral nervous manifestations in Europe and the United States (2), but not in Japan. Evaluation of the relationship between fo late deficiency and neurological symptoms is difficult, since most patients suffer from nutritional disorders or excessive alcohol intake, resulting in deficiency of nutri ents other than folate (3) . In addition, dysfunctions in the central nervous system (CNS) including psychiatric symptoms can induce anorexia or malnutrition, wors ening further the vitamin deficiency in a vicious circle (4) .
The administration of thiamin and cobalamin has re cently become the standard treatment recipe for Japanese patients with neurological disorders, espe cially those with a history of excessive alcohol intake, gastrointestinal (CI) symptoms or surgery. In fact, most of the patients examined in the present study had been given thiamin and cobalamin before they were referred * To whom correspondence should be addressed .
to our clinic.
Moreover, folate deficiency is reported to be much less frequent in Japan than in Europe or the United States (5) . Since neurological symptoms are ameliorated by fo late supplements in most cases, we investigated the fre quency of folate-responsive neurological patients in our clinic and the characteristics of folate-responsive pa tients, compared with folate-resistant neurological pa tients. This study is the first to elucidate factors which determine the effectiveness of folate therapy and to dis close the frequency of folate-deficient neurological dis eases in Japan. Serum folate concentration was measured by chemi luminescence (7) . The normal range for the serum fo late level was assigned as 4.0-12.0ng/mL.
We consid ered patients with serum folate levels lower than the normal limit (<4ng/mL) as folate-deficient.
Statistical analyses were performed using the x2 test and ANOVA t-test. The statistical software used for this analysis was JMP. x2 values were included in the paper when a significant difference was found for categorical data. Difference among various types of neuropathy; de myelination (D), axonopathy (A) and combined neu ropathy (C). Serum folate levels were not significantly (p>0.1) different among groups. Dots, vertical bars and broken horizontal bars show means, standard er rors and deviations, respectively. Folate-deficient neurological patients poorly responded to the folate supplements when they were treated with tube feeding (x2=9.84, p<0.002) or continuous drip infusion (x2=5.69, p<0.02), or had malabsorption symptoms (x2=8.04, p<0.005).
RESULTS
Folate responsiveness was not significantly different between those with and without a history of gastrectomy (p>0.5).
All patients treated with anticonvulsants responded to folate supplements (x2=3.49, p=0.062) and the his tory of alcohol intake did not influence the effect of fo late supplements (p>0.5). Multivariate logistic regres sion analysis showed that folate therapy was not effec tive in neurological patients with malabsorption (x2=5.75, p<0.02) or continuous drip infusion (x2=3.88, p<0.05) independent of other factors.
DISCUSSION
Folate has been known to participate biochemically in the transfer of one carbon units, and to serve as a hy drogen donor for the hydroxylation of aromatic amino acids including phenylalanine, tyrosine and tryptophan (1, 8, 9) . Folate deficiency is thought to cause dementia (3, 10) , subacute combined degeneration (10, 11) , neu ropathy (12, 13), multiple sclerosis (14, 15) , and can cer in the GI tract (16) . Folate deficiency is a common vitamin deficiency occurring in approximately 10% of the U.S. population (17) . However, the frequency and importance of folate deficiency has not been fully eluci dated in neurological diseases, especially in Japan. Thus, folate needs to be examined in serum and given to patients with malnutrition.
The major causes of folate deficiency found in this study were disorders in the GI tract, excessive alcohol intake or anticonvulsants as described previously (12, 18, 19) . In addition, we found 8 neurological patients without previously reported causes (20) (21) (22) . These 8 cases had been treated with various drugs such as an tibiotics or psychomimetics. Folate deficiency could be caused by the side effects as-yet-unidentified drugs, since many chemicals are known to interfere with fo late metabolism (19) . Drugs responsible for folate defi ciency should be identified.
Many neurological symptoms have been reported to be associated with folate deficiency, but the frequency of the association has not been investigated in detail. The most common neurological disorder was neuropathy, followed by dementia. Neuropathy was observed in the lower extremities more severely than the upper extremi ties. Sensory axonopathy was dominant in the folate de ficient neuropathy demonstrated electrophysiologically, consistent with previous reports (12, 22) , while multi variate analysis did not detect any differences among subtypes of folate-deficient neuropathy. Axonopathy re sponded more readily to folate therapy, suggesting that axonopathy is a prototype of folate-deficient neuropathy which can be modified by other factors concomitant with diseases, leading to demyelination.
We found 7 cases with gustatory impairment (dys geusia) and folate administration improved this after 60 d. Commonly dysgeusia induced a loss of appetite in folate-deficient patients and worsened malnutrition and folate deficiency. Therefore, further studies on folate-re sponsive dysgeusia with more patients are needed to clarify whether it is due to neuropathy or a GI tract dis order.
The present study revealed a correlation between sex and folate-deficient neurological diseases. The serum fo late level was higher in male than female folate-defi cient patients. Male patients more frequently exhibited demyelination or motor-dominant neuropathy and ane mia, which appeared to be more responsive to folate therapy. The male predominance could be explained ei ther by history of alcohol (x2=8.89, p<0.005) or of gastrectomy (x2=4.00, p<0.05) or by a higher serum folate threshold of neurological manifestation than fe males. The latter possibility could be confirmed by the lower incidence of demyelination and anemia, and lower serum folate level in females. Folate administration improved neurological symp toms in 24 of 36 cases after 2 months. In other studies, folate was given for longer periods such as 9 to 39 months (12) or 50 to 240 d (25) . We examined the ef fect after 2 months, but nonresponders are expected to be ameliorated by longer treatment. The present study emphasized the importance of ex amination of serum folate concentrations and, if the concentration is low, supplementing with folate. Several groups had folate levels measured in the cerebrospinal fluid (CSF) (15) . We determined serum folate levels, since CSF folate levels correlate well with serum folate levels (15) , while the measurement in serum is more conventional and harmless in practical medicine or for common diseases like neuropathy or dementia. Examination of folate levels and treatment with folate are potentially useful in daily practice in Japan.
